To report and discuss the multi-domain impact of elosulfase alfa , with focus on tertiary and composite endpoints , in the @-week , randomized , double-blind , placebo-controlled phase @ trial in patients with Morquio A syndrome ( mucopolysaccharidosis IVA ) .